Ask Warren

NGeneBio

354200 · KOSDAQ · ₩354200 · 엔젠바이오

₩695▲ ₩53 (8.26%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩12B₩12B₩12B₩5.4B₩1.8B₩2B₩717M₩2.1B
Cost of sales₩11B₩11B₩11B₩4.4B₩1.5B₩1B₩1.1B₩1B
Gross profit₩1.9B₩1.4B₩1.5B₩1B₩303M₩999M−₩336M₩1B
Operating income−₩1.2B−₩1.6B−₩1.9B−₩1.6B−₩1.9B−₩2.9B−₩4.5B−₩4.1B
Net income₩742M−₩4.2B−₩4.8B₩4.1B−₩3.1B−₩3B−₩9.3B−₩1.8B
Net income to shareholders−₩3.4B−₩4.2B₩4.5B−₩1.9B−₩5.4B−₩2.7B−₩2.9B−₩4.1B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩71B₩72B₩72B₩44B₩31B₩29B₩33B₩34B
Current assets₩23B₩23B₩24B₩25B₩15B₩9B₩12B₩12B
Cash and equivalents₩3B₩3B₩1.9B₩3B₩9B₩2B₩4.4B₩5.5B
Total liabilities₩52B₩50B₩50B₩28B₩14B₩15B₩15B₩24B
Current liabilities₩51B₩48B₩48B₩27B₩12B₩12B₩13B₩21B
Borrowings₩36B₩32B₩33B₩16B₩6.8B₩6.9B₩6.7B₩11B
Total equity₩19B₩22B₩23B₩16B₩18B₩15B₩18B₩9.6B
Shareholders' equity₩19B₩23B₩23B₩16B₩18B₩14B₩17B₩8.7B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩1.4B₩1B−₩2.2B−₩2.5B−₩1.5B−₩2.3B−₩745M−₩5.5B
Capital spending₩19M₩781M−₩2.4B₩2.4B₩15M₩4M₩3.5M−₩5.6M
Free cash flow−₩1.4B₩238M−₩4.6B−₩4.9B−₩1.5B−₩2.3B−₩749M−₩5.5B

Consolidated where available. Amounts in won.

Also known as: NGeneBio / 엔젠바이오 / 354200 / KRX:354200

Source: KRX statistical information